• French Translation and Validation of the PEYronie's Disease QUESTionnaire

  NCT05768867

  CompletedObservationalUpdated Aug 27, 2024
• Validation of the French Version of the Health Assessment Questionnaire II (HAQ-II) for Rheumatoid Arthritis

  NCT03249467

  CompletedObservationalUpdated Aug 25, 2017
• Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease

  NCT06998316

  Not yet recruitingObservationalUpdated May 31, 2025
• Validation of a Questionnaire in the French Language for the Patient Experience in Radiotherapy

  NCT07133594

  Active, not recruitingInterventionalNot ApplicableUpdated Aug 21, 2025
• Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease

  NCT01891214

  CompletedObservationalUpdated Feb 15, 2017
• Validation of a Tolerability Questionnaire in Rheumatoid Arthritis

  NCT02401620

  Unknown statusObservationalUpdated Mar 30, 2015

ClinicalTrials.gov ID

NCT03642795

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

150Estimated

Last Update Posted

Dec 3, 2025Actual

Start Date

Jun 23, 2022Actual

Primary Completion Date

Mar 2029Estimated

Completion Date

Mar 2029Estimated

Official Title

Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology): Specific Tool for Evaluation of Observance of Rheumatology Treatment

Brief Summary

The purpose of this study is to develop a French language version of the Compliance-Questionnaire-Rheumatology for use in French and Francophone rheumatology services

• Rheumatoid Polyarthritis

• Questionnaire

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• The patient must have given their free and informed consent and signed the consent form
• The patient must be a member or beneficiary of a health insurance plan
• The patient is at least 18 years old
• The patient has rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria, treated orally or subcutaneously with MTX for at least 3 months with a stable (unchanged) dosage for at least 1 month, and a stable (unchanged) route of administration for at least 1 month. And no planned change in Methotrexate intake at least until the second study visit. Other treatments at the same time are authorized

Exclusion Criteria:

• The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
• The subject refuses to sign the consent
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship
• The subject has a contraindication to taking methotrexate (including a patient with a desire to become pregnant).

Observational Model

Case-Only

Time Perspective

Prospective

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

drc@chu-nimes.fr04.66.68.42.36